In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CFSAN program priorities

This article was originally published in The Rose Sheet

Executive Summary

FDA is requesting comments on FY 2005 program priorities for the Center for Food Safety & Applied Nutrition, agency announces in a June 24 Federal Register 1notice. CFSAN anticipates "there will be considerable continuity between the 2004 and 2005 workplans," the notice states. FY 2004 "A" list priorities include a review of phthalates and completion of a labeling guidance on alpha hydroxy acid-containing products (2"The Rose Sheet" May 10, 2004, p. 5). Workplan also will follow the format of the FY 2004 plan, which was divided into four sections - assessing food safety and security, improving nutrition and dietary supplement safety, assuring food and cosmetic safety and assuring food safety: cross cutting areas. Comments are due Aug. 9, and the program priorities will be released this fall, the notice states. FDA's fiscal year begins Oct. 1...

You may also be interested in...



Phthalate Cosmetics Survey Placed On CFSAN Priority List

Amid growing controversy over the use of phthalates in cosmetics, FDA's Center for Food Safety & Applied Nutrition announced that a review of the chemicals is one of the Office of Cosmetics & Colors "A" list priorities for fiscal 2004 (ending Sept. 30)

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012238

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel